Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy
NCT02351856Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emprumapimod in LMNA-related dilated cardiomyopathy, sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 282 weeks, Number of Participants With Change From Baseline Value in Clinical Laboratory Hematology Test Results to Worst Value up to 282 weeks and 4 more. Started Feb 2015; status: completed.
02
Drugs
emprumapimod
03
Conditions
LMNA-related dilated cardiomyopathy
Beyond the preview
Go deeper on NCT02351856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351856.